The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, United Therapeutics's share price is $223.045.
United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $37.40. Hence, United Therapeutics's PS Ratio for today is 5.96.
Warning Sign:
United Therapeutics Corp stock PS Ratio (=5.93) is close to 5-year high of 6.53
The historical rank and industry rank for United Therapeutics's PS Ratio or its related term are showing as below:
UTHR'
s PS Ratio Range Over the Past 10 Years
Min: 2.16 Med: 3.7 Max: 7.05
Current: 5.96
During the past 13 years, United Therapeutics's highest PS Ratio was 7.05. The lowest was 2.16. And the median was 3.70.
UTHR's PS Ratio is ranked better than 67.39% of 1018
companies
in the Biotechnology industry
Industry Median: 11.82
vs UTHR: 5.96
United Therapeutics's Revenue per Sharefor the
three
months ended in Jun. 2022 was $9.71.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $37.40.
Warning Sign:
United Therapeutics Corp revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of United Therapeutics was 7.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 9.90% per year.
During the past 13 years, United Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 260.90% per year. The lowest was -4.70% per year. And the median was 28.20% per year.
Back to Basics: PS Ratio
United Therapeutics PS Ratio Historical Data
The historical data trend for United Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
United Therapeutics Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
PS Ratio
3.85
2.94
2.66
4.56
6.06
United Therapeutics Quarterly Data
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
PS Ratio
5.18
5.20
6.06
4.83
6.30
Competitive Comparison
For the Biotechnology subindustry, United Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
United Therapeutics PS Ratio Distribution
For the Biotechnology industry and Healthcare sector, United Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where United Therapeutics's PS Ratio falls into.
United Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
United Therapeutics's PS Ratio for today is calculated as
United Therapeutics's Share Price of today is $223.045.
United Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $37.40.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
United Therapeutics (NAS:UTHR) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
United Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of United Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.42(0.64%) Volume: 171,966 3:49PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:UTHR has been successfully added to your 
